Study of GI001 for B-cell lymphoma and leukemia that has returned or not responded
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new treatment called GI001 for people with B-cell lymphoma or B-cell leukemia that has come back or hasn't responded to previous treatments. It aims to see if GI001 can help when other options have failed, and it may be an option if you haven't had CAR-T therapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need a diagnosis of a B-cell lymphoma or B-cell leukemia that is CD19-positive and has come back or not responded to standard treatment.
- Your cancer must be measurable (a tumor that can be seen on scans or leukemia cells in your blood or bone marrow).
- You should be in reasonably good health, with adequate organ function (like liver, kidney, heart) and able to care for yourself (ECOG 0-2).
- You must not have had certain prior treatments like CAR-T therapy, anti-CD19 therapy, or certain chemo within specific time periods before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that came back or did not improve after other treatments. The therapy uses your own immune cells to fight the cancer, and the study aims to see if it is safe and effective.
This trial tests a new cell therapy called GI001 for patients with certain types of B-cell lymphoma or leukemia that have returned or not responded to previous treatments. It aims to see if this therapy can help control the disease.
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
This trial tests a new type of CAR T-cell therapy that targets two proteins on cancer cells (CD20 and CD19) for B-cell cancers like lymphoma and leukemia that have come back or not responded to other treatments. It might help you if your cancer hasn't been controlled by standard options.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.